News for Summit Therapeutics Inc. (SMMT)

We recently compiled a list of the 10 Hot Growth Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Summit Therapeutics Inc.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Deep-pocketed investors have adopted a bullish approach towards Summit Therapeutics SMMT, and it's something market players shouldn't ignore. Our tracking of pu...

Cash Position: Approximately $412 million at the end of 2024.Debt Status: Debt-free as of the end of 2024.GAAP R&D Expenses: $150.8 million for the full year 2

Summit Therapeutics Inc (SMMT) has released its financial results and operational updates for the fourth quarter and year ended December 31, 2024. The company h

Summary Summit Therapeutics Inc (SMMT) announced a strategic collaboration with Pfizer Inc. to evaluate the efficacy of ivonescimab, a novel PD-1/VEGF bispecifi

Summit Therapeutics Inc (SMMT) is a biopharmaceutical company with a focus on developing novel antibiotics for serious infectious diseases.The company's lead p

HONG KONG, Feb. 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors. Click to read why SMMT stock is a Strong Buy.

The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading.

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to take a look at where Summit Therapeutics Inc.

Discover insights from Summit Therapeutics' Q4 2024 earnings call, highlighting the Pfizer collaboration, ivonescimab trial expansions, and strong financial...

Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2024 Earnings Conference Call February 24, 2025 9:00 AM ETCompany ParticipantsDave Gancarz - Chief Business and...

Summit Therapeutics (SMMT) enters a clinical trial collaboration to evaluate its cancer drug, ivonescimab, in combination with Pfizer (PFE) antibody drug conjugates across multiple solid tumor settings.

Summit Therapeutics Inc. (NASDAQ: SMMT) (”œSummit,” ”œwe,” or the ”œCompany”) today reports its financial results and provides an update on operationa

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investiga

On December 31, 2024, Darwin Global Management, Ltd. (Trades, Portfolio) executed a significant transaction involving Insmed Inc., a global biopharmaceutical co

Summit Therapeutics Inc (SMMT), a biopharmaceutical company focused on oncology, announced on February 11, 2025, the grant of inducement awards comprising optio

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective t